This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Public Access to Clinical Data: The evolution of initiatives from the European Medicines Agency
Published on: May 8, 2018
It remains the mission of all stakeholders to get high quality medicines to patients as time- and cost-efficiently as possible. To facilitate this process, the EMA has taken a number of initiatives to make clinical data, submitted to support marketing authorisations, increasingly available to industry and the general public alike.
However, it is important that the data made public is presented in such a way that it is not possible to identify specific individuals who participated in a clinical study and to ensure that their personal data is appropriately protected, in line with current legislation.
In this paper, you will see the latest data transparency updates for Policy 70 and the timelines for Clinical Reports.
Download the full resource now
Fill in the form to download the content